share: Rivaroxaban (Xarelto) Effective for Atrial Fibrillation Patients with High Stroke Risk
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn more, see:
Rivaroxaban as Effective as Warfarin for Stroke Prevention in Atrial Fibrillation
http://bit.ly/o0eUXR
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.
Add a Comment1 Comments
Thank you for these links, Mellanie!
We have lots of readers interested in A-Fib and this will provide more information that can help them advocate for themselves.
Best,
September 6, 2011 - 11:23am~Susan
This Comment